Patrys Limited (AU:PAB) has released an update.
Patrys Limited has announced a delay in the clinical development of its cancer treatment drug PAT-DX1 due to ongoing specification testing, which is now expected to conclude by the end of July 2024. This testing is crucial for releasing the drug for clinical trials, and the delay affects the commencement of clinical activities. The company is focused on developing therapies for various cancers using its deoxymab platform and has committed to updating stakeholders on any further developments.
For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.
